知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

29 records (took 0.041 seconds)

    CLK-peptide and SLK-peptide
    1.
    发明授权
    CLK-peptide and SLK-peptide 有权
    CLK-肽和SLK-肽

    公开(公告)号：US07662783B2

    公开(公告)日：2010-02-16

    申请号：US11251442

    申请日：2005-10-14

    Applicant: Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    Inventor： Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    IPC: A61K38/10

    CPC classification number: A61K38/08 ,  A61K38/10

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.

    Abstract translation: 本发明描述了通过施用特异性结合蛋白水解或变性的IV型胶原蛋白的拮抗剂来抑制组织中的血管发生的方法，其具有比IV型胶原天然三螺旋形式更大的亲和力。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。 本发明还描述了使用所述拮抗剂结合放射疗法治疗肿瘤的方法和包括拮抗剂和放射治疗的疗法。

    STQ Peptides
    2.
    发明申请
    STQ Peptides 审中-公开
    STQ肽

    公开(公告)号：US20090226369A1

    公开(公告)日：2009-09-10

    申请号：US12118288

    申请日：2008-05-12

    Applicant: Peter C. Brooks ,  Abebe Akalu

    Inventor： Peter C. Brooks ,  Abebe Akalu

    IPC: A61K51/08 ,  A61K38/08 ,  A61K38/10 ,  A61K49/14

    CPC classification number: C07K7/08

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.

    Abstract translation: 本发明描述了通过施用与蛋白水解或变性层粘连蛋白特异性结合的拮抗剂，以比天然形式的层粘连蛋白具有更大的亲和力来抑制组织中血管生成的方法。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。

    CLK-peptide and SLK-peptide
    3.
    发明授权
    CLK-peptide and SLK-peptide 有权
    CLK-肽和SLK-肽

    公开(公告)号：US08133471B2

    公开(公告)日：2012-03-13

    申请号：US12643926

    申请日：2009-12-21

    Applicant: Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    Inventor： Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    IPC: A61K51/00

    CPC classification number: A61K38/08 ,  A61K38/10

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.

    Abstract translation: 本发明描述了通过施用特异性结合蛋白水解或变性的IV型胶原蛋白的拮抗剂来抑制组织中的血管发生的方法，其具有比IV型胶原天然三螺旋形式更大的亲和力。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。 本发明还描述了使用所述拮抗剂结合放射疗法治疗肿瘤的方法和包括拮抗剂和放射治疗的疗法。

    CLK-PEPTIDE AND SLK-PEPTIDE
    4.
    发明申请
    CLK-PEPTIDE AND SLK-PEPTIDE 有权
    CLK-PEPTIDE和SLK-PEPTIDE

    公开(公告)号：US20100226852A1

    公开(公告)日：2010-09-09

    申请号：US12643926

    申请日：2009-12-21

    Applicant: Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    Inventor： Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    IPC: A61K51/00 ,  A61K49/00 ,  G01N33/53

    CPC classification number: A61K38/08 ,  A61K38/10

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.

    Abstract translation: 本发明描述了通过施用特异性结合蛋白水解或变性的IV型胶原蛋白的拮抗剂来抑制组织中的血管发生的方法，其具有比IV型胶原天然三螺旋形式更大的亲和力。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。 本发明还描述了使用所述拮抗剂结合放射疗法治疗肿瘤的方法和包括拮抗剂和放射治疗的疗法。

    STQ peptides
    5.
    发明授权
    STQ peptides 有权
    STQ肽

    公开(公告)号：US07387998B2

    公开(公告)日：2008-06-17

    申请号：US10797626

    申请日：2004-03-09

    Applicant: Peter C. Brooks ,  Abebe Akalu

    Inventor： Peter C. Brooks ,  Abebe Akalu

    IPC: A61K38/00 ,  A61K38/04

    CPC classification number: C07K7/08

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.

    Abstract translation: 本发明描述了通过施用与蛋白水解或变性层粘连蛋白特异性结合的拮抗剂，以比天然形式的层粘连蛋白具有更大的亲和力来抑制组织中血管生成的方法。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。

    Antagonists and methods for inhibiting angiogenesis
    8.
    发明授权
    Antagonists and methods for inhibiting angiogenesis 有权
    拮抗剂和抑制血管发生的方法

    公开(公告)号：US08025883B2

    公开(公告)日：2011-09-27

    申请号：US11227524

    申请日：2005-09-15

    Applicant: Peter C. Brooks ,  Jingsong Xu ,  Eric Petitclerc

    Inventor： Peter C. Brooks ,  Jingsong Xu ,  Eric Petitclerc

    IPC: A61K39/395 ,  C07K14/705 ,  C07K16/28 ,  C07K14/78 ,  C07K16/30

    CPC classification number: A61K39/3955 ,  A61K31/00 ,  A61K31/337 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K2317/73 ,  C07K2317/76 ,  A61K2300/00

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis is normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.

    Abstract translation: 本发明描述了通过施用特异性结合蛋白水解或变性胶原但不与胶原天然三重螺旋形式结合的拮抗剂来抑制组织中血管生成的方法。 本发明的拮抗剂可以靶向例如I型，II型，III型，IV型，V型及其组合的变性胶原。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及使用这种拮抗剂作为血管发生诊断标志物的方法是体内和体外的正常或患病组织。 拮抗剂包括被称为HUI77，HUIV26和XL313的单克隆抗体。

    CLK-peptide and SLK-peptide
    10.
    发明授权
    CLK-peptide and SLK-peptide 失效
    CLK-肽和SLK-肽

    公开(公告)号：US07601694B2

    公开(公告)日：2009-10-13

    申请号：US10782728

    申请日：2004-02-18

    Applicant: Peter C. Brooks ,  Jennifer M. Roth

    Inventor： Peter C. Brooks ,  Jennifer M. Roth

    IPC: A61K38/10

    CPC classification number: A61K38/10 ,  A61K38/08

    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.

    Abstract translation: 本发明描述了通过施用特异性结合蛋白水解或变性的IV型胶原蛋白的拮抗剂来抑制组织中的血管发生的方法，其具有比IV型胶原天然三螺旋形式更大的亲和力。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。

Patent Agency Ranking